Join
Live feed
·
PRReleasevia Quantisnow
OnKure Therapeutics Inc. logo

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

ByQuantisnow·Wall Street's wire, on your screen.
OKUR· OnKure Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OKUR (OnKure Therapeutics Inc.) and more on Quantisnow.